Sharps Technology, Inc. recently announced a $50+ million sales agreement with a US-based pharma company, along with plans for expanding manufacturing in Hungary. The initial production and commercial deliveries are set to begin in Q1 2025. The company has also signed agreements to sell current inventory of SecureGard syringes in Hungary, with shipments and revenue already underway. These developments have led to increased interest in the company’s high-quality syringe products, especially as demand for injectable therapies continues to rise.
The CEO, Robert Hayes, highlighted the importance of these agreements in a shareholder letter, emphasizing the potential for revenue growth and expansion in Hungary. The company is also working on finalizing the acquisition of manufacturing assets in South Carolina. These developments have helped Sharps regain compliance with NASDAQ’s listing rules.
Sharps Technology specializes in innovative drug delivery systems, offering patented smart-safety syringes with low waste features and active safety mechanisms. The company’s products are aimed at meeting the growing demand for high-quality drug delivery solutions in the healthcare industry.
Looking ahead, Sharps Technology is well-positioned to capitalize on upcoming opportunities and is optimistic about its future growth. For more information, visit the company’s website.
Source
Photo credit www.globenewswire.com